Table 2 Baseline characteristics of participants
Placebo (n = 23) | Vitamin D2 (n = 23) | P-value | |
|---|---|---|---|
Sex, n (%) | 0.7 | ||
Male | 11 (23.9) | 12 (26.1) | |
Female | 12 (26.1) | 11 (23.9) | |
Age (year) | 52.4 ± 5.7 | 51.3 ± 4.7 | 0.4 |
Educational level, n (%) | 0.5 | ||
Primary | 6 (13.0) | 4 (8.7) | |
Diploma | 10 (21.7) | 6 (13.0) | |
Bachelor or master degree | 7 (15.2) | 13 (28.8) | |
Employed, n (%) | 0.7 | ||
Yes | 14 (30.4) | 15 (26.3) | |
No | 9 (19.7) | 8 (17.4) | |
Aspirin use, n (%) | 0.7 | ||
Yes | 10 (21.7) | 11 (23.9) | |
No | 13 (28.3) | 12 (26.1) | |
Diabetes duration (year) | 6.7 ± 3.0 | 5.8 ± 2.6 | 0.3 |
WC (cm) | 97.2 ± 8.5 | 96.6 ± 7.4 | 0.8 |
BMI (kg/m2) | 27.5 ± 1.6 | 26.8 ± 1.4 | 0.6 |
Physical activity, n (%) | 0.2 | ||
Mild | 12 (26.1) | 17 (37) | |
Moderate | 10 (21.7) | 6 (13) | |
High | 1 (2.2) | 0 (0) | |
HbA1c (%) | 7.9 ± 1.1 | 7.4 ± 0.8 | 0.06 |
Metformin dose (mg/day) | 1282.6 ± 253.4 | 1065.2 ± 274 | 0.01 |
Gliclazide dose (mg/day) | 73.1 ± 29.1 | 70 ± 36.8 | 0.7 |